Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carboplatin + enzastaurin + pemetrexed
- Development stage
- Phase 2
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination chemotherapy regimen that includes carboplatin (a platinum-based chemotherapy agent), enzastaurin (an oral serine/threonine kinase inhibitor targeting protein kinase C-beta and the phosphatidylinositol-3-kinase/AKT pathway), and pemetrexed (an antifolate metabolic inhibitor). The combination was studied in clinical trials for the treatment of advanced non-small cell lung cancer (NSCLC). Clinical trials have shown that enzastaurin did not add to the activity of pemetrexed-carboplatin, and this specific three-drug combination does not warrant further study in NSCLC based on trial results.
02
Targets
ABCB1 (P-glycoprotein)ABCG2 (Breast cancer resistance protein)ATIC (Aminoimidazole carboxamide ribonucleotide transformylase)DNADHFR (Dihydrofolate reductase)GART (GAR transformylase)GSK3 (Glycogen synthase kinase 3 beta)PRKCA (Protein kinase C alpha)PRKCB (Protein kinase C beta)PRKCE (Protein Kinase C epsilon)PRKCG (Protein kinase C gamma)TS (Thymidylate synthase)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)
Beyond the preview
Go deeper on carboplatin + enzastaurin + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carboplatin + enzastaurin + pemetrexed.